Search Results

You are looking at 1 - 10 of 130 items for :

  • "mastectomy" x
  • All content x
Clear All
Full access

Shaneli A. Fernando and Stephen B. Edge

clinical practice guidelines in oncology. Version 1 , 2007 . Available at: http://www.nccn.org/physician_gls/PDF/breast.pdf . Accessed January 25, 2007 . 2. Recht A Gray R Davidson NE . Locoregional failure 10 years after mastectomy and

Full access

James Sun, Brittany J. Mathias, Christine Laronga, Weihong Sun, Jun-Min Zhou, William J. Fulp, John V. Kiluk, and M. Catherine Lee

less morbidity, including lymphedema. Notably, most patients had T1N1 disease, and only 18% received mastectomy. These studies, among several others, form the basis for de-escalation of axillary surgery in early-stage breast cancer after BCS, which is

Full access

Michael J. Hassett, Wei Jiang, Melissa E. Hughes, Stephen Edge, Sara H. Javid, Joyce C. Niland, Richard Theriault, Yu-Ning Wong, Deborah Schrag, and Rinaa S. Punglia

treatments provided to patients who experienced an SBE and to identify independent determinants of mastectomy or AET for SBEs. We hypothesized that younger patients and those who received RT or AET for their initial DCIS treatment could be more likely to

Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, George Somlo, Neal S. Topham, John H. Ward, Eric P. Winer, and Antonio C. Wolff

invasive disease, even if microinvasive, on pathology review or at reexcision, mastectomy, or axillary lymph node staging should be treated according to the stage-appropriate guideline for invasive carcinoma. Lobular Carcinoma In Situ: After a

Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Jasgit Sachdev, Mary Lou Smith, George Somlo, John H. Ward, Antonio C. Wolff, and Richard Zellars

pregnant during breast cancer treatment (see page 160). Locoregional Treatment Several randomized trials document that mastectomy with axillary lymph node dissection is equivalent to breast-conserving therapy with lumpectomy, axillary dissection

Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Mohammad Jahanzeb, Krystyna Kiel, Britt-Marie Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, George Somlo, Richard L. Theriault, Neal S. Topham, John H. Ward, Eric P. Winer, and Antonio C. Wolff

treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group . J Clin Oncol 1996 ; 14 : 1558 – 1564 . 54 Clarke M Collins R Darby S . Effects of

Full access

Mei-Chin Hsieh, Lu Zhang, Xiao-Cheng Wu, Mary B. Davidson, Michelle Loch, and Vivien W. Chen

microscopically confirmed stage I–III disease diagnosed in 2011 and who had undergone total mastectomy or breast-conserving surgery plus radiation. Eligibility was restricted to patients with histologic codes 8050, 8140, 8201, 8211, 8401, 8480, 8481, and 8500

Full access

Rondi M. Kauffmann, Leanne Goldstein, Emily Marcinkowski, George Somlo, Yuan Yuan, Philip H.G. Ituarte, Laura Kruper, Leslie Taylor, and Courtney Vito

/radiation, or mastectomy. 1 When breast conservation is used, the risk of local recurrence is higher than with mastectomy. 1 Antiestrogen (anti-e) therapy, in the form of either tamoxifen or an aromatase inhibitor (AI), may be used to reduce the risk of local

Full access

Nawin Kuntaraksa

formation. Materials and Methods: A randomized control trial was conducted between January 2014 and November 2017. 68 consecutive patients undergoing mastectomy with axillary lymph node dissection by one experienced surgeon. The patients were randomly

Full access

Stephen B. Edge

outcome advantage over breast-conserving therapy (BCT). One concern with BCT has been a higher rate of local recurrence compared with mastectomy, with initial studies before the routine use of systemic therapy reporting rates of 10% to 20% with BCT. 2